Fund Basics

Daily Data as of 3/22/2023

Closing Market Price $16.86
NAV $19.40
Premium/Discount -13.09%
Daily Volume 132,588
Net Assets $927,377,579
Common Shares Outstanding 47,802,968
Percent Leveraged N/A
52 Week Average Premium/Discount -7.63%
52 Week High/Low Market Price $
52 Week High/Low Market NAV $
Distribution Information as of 2/15/23

Distribution Information

Current Distribution Rate 9.33%
Quarterly Dividend Per Share $0.4200
Ex-Dividend Date February 24, 2023
Payable Date March 31, 2023

Complete listing of historical distributions  

Current quarter’s distribution per share annualized, plus excise distribution, divided by the last closing date market price per share. The Fund’s first quarter 2023 distributions were estimated to be comprised of return-of-capital. The distribution rate alone is not indicative of Fund performance. The character of the current distributions was estimated and disclosed in a Section 19(a) Notice located under the “Investor Information” section of the Fund’s website. Please note that the distribution classifications are preliminary and certain distributions may be re-classified at year end. Please refer to year-end tax documents for the final classifications of the Fund’s distributions for a given year.

1 This excise distribution represents a one-time payment to satisfy annual tax distribution requirements.


Fiscal Year-End 9/30
Portfolio Manager Tekla Capital Management
Shareholder Servicing Agent Destra Capital Advisors

HQH Fact Card

Investment Objective

Tekla Healthcare Investors (HQH) is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQH. HQH primarily invests in the healthcare industry (including biotechnology, medical devices, and pharmaceuticals). The Fund's objective is to provide long-term capital appreciation through investments in companies in the healthcare industry believed to have significant potential for above-average long-term growth. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies. Management believes this provides a unique opportunity not usually available to mutual fund investors.